82 avenue Raspail • 94250 • Gentilly • France

Sanofi

Sanofi to invest €350 million in Canadian vaccine facility

By Sanofi ·

New Toronto facility is one of the largest-ever investments by Sanofi in a single building.

Sanofi is investing €350 million (CAD $500 million) for the construction of a new state-of-the-art vaccine manufacturing facility at the Sanofi Pasteur Canadian headquarters in Toronto, Ontario. The investment bolsters the company's Canadian operations and its commitment to advancing public health around the world.

Sanofi to invest €350 million in Canadian vaccine facility

"Canada has a strong legacy in the research and development of vaccines. With this investment, Sanofi is renewing our longstanding commitment to making Canada central in our effort to protect and improve human health across the globe," said David Loew, Executive Vice President and Head of Sanofi Pasteur. "Vaccines save three million lives every year and this new facility will take us one step closer to a world where no one suffers or dies from a vaccine-preventable disease."

The new facility will allow Sanofi Pasteur, the vaccines global business unit of Sanofi, to meet the growing demand of five-component acellular pertussis (5-acP) antigen. Upon completion in 2021, the new building will also be equipped to produce the antigens used in the diphtheria and tetanus vaccines.

"This project is one of the most important investments for the Sanofi global industrial network," said Philippe Luscan, Executive Vice President, Global Industrial Affairs, Sanofi. "It demonstrates our continued commitment to manufacturing excellence and to better serving our vaccines portfolio to people all over the world."

Read More


Go to company page 

Categories

Market News

Other news in “Market News”

Manufacturing collaboration to advance PMD-026 toward IND

Manufacturing collaboration to advance PMD-026 toward IND 

18 Apr 2018
Wacker acquisition increases cost-effective pharmaceutical production

Wacker acquisition increases cost-effective pharmaceutical production 

18 Apr 2018
Cambrex invests in new continuous flow technology

Cambrex invests in new continuous flow technology 

17 Apr 2018